drugset
Drugs / Vi-CRM
last change Oct 2024 re-read 3 minutes ago

Vi-CRM

also known as TYPHIBEV · Vi capsular polysaccharide-CRM197 conjugate vaccine

Vaccine

Developed for
typhoid fever
Investigated by
Groupe de Recherche Action en Sante · Kathleen Neuzil

Trials 1

today NCT07624175 · Ph 2
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07624175 Aug → Oct 2024 typhoid fever Kathleen Neuzil Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Vi-CRM ClinicalTrials.gov intervention name — accepted as the source's own label NCT07624175 ↗
Known as TYPHIBEV “Received one intramuscular dose of Vi-CRM (TYPHIBEV®)” NCT07624175 ↗
Known as Vi capsular polysaccharide-CRM197 conjugate vaccine “Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM” NCT07624175 ↗
Modality Vaccine “Typhoid conjugate vaccine: Vi capsular polysaccharide conjugated to CRM197 carrier protein, administered as 0.5mL intramuscularly” NCT07624175 ↗
Route Intramuscular “administered as 0.5mL intramuscularly” NCT07624175 ↗